Sarah Horn1, Hayley Richardson2, Sharon X Xie3, Daniel Weintraub4, Nabila Dahodwala5. 1. University of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: Sarah.Horn@uphs.upenn.edu. 2. University of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: rhayley@pennmedicine.upenn.edu. 3. University of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: sxie@pennmedicine.upenn.edu. 4. University of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: Daniel.Weintraub@uphs.upenn.edu. 5. University of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: Nabila.Dahodwala@uphs.upenn.edu.
Abstract
INTRODUCTION: Psychosis is common among patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Limited data exist on the most effective therapies. METHODS: Retrospective cohort study comparing patients with PD or DLB initiated on quetiapine or pimavanserin for psychosis. Primary outcome was time to discontinuation of pimavanserin or quetiapine using Kaplan-Meier survival analysis. We hypothesized the rate of antipsychotic discontinuation would be lower in the pimavanserin group. Subjects were included if the indication for treatment was psychosis and excluded if there was a history of major mental illness or no follow up data were available. RESULTS: Forty-seven patients were included in the quetiapine cohort and 45 in the pimavanserin cohort. Patients in the pimavanserin cohort were more likely to have a diagnosis of DLB (33% vs. 11%, P = 0.01) and to have been prescribed an antipsychotic previously (62% vs. 6%, P < 0.01); otherwise, the groups were similar. Time to discontinuation analysis, which accounts for efficacy, safety and tolerability, revealed a lower early pimavanserin discontinuation rate and a higher late pimavanserin discontinuation rate (HR < 1 before day 43, HR > 1 after day 43; P = 0.04). There was no difference in mortality in the pimavanserin group compared to the quetiapine group (HR 0.37, 95% CI 0.06 to 2.45; P = 0.88). More individuals had a documented secondary indication for taking quetiapine than pimavanserin (38% vs. 4%; P = 0.001). CONCLUSION: Accounting for efficacy, safety and tolerability, pimavanserin may be more clinically useful for promptly managing psychosis, while quetiapine may confer additional secondary benefits long-term.
INTRODUCTION:Psychosis is common among patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Limited data exist on the most effective therapies. METHODS: Retrospective cohort study comparing patients with PD or DLB initiated on quetiapine or pimavanserin for psychosis. Primary outcome was time to discontinuation of pimavanserin or quetiapine using Kaplan-Meier survival analysis. We hypothesized the rate of antipsychotic discontinuation would be lower in the pimavanserin group. Subjects were included if the indication for treatment was psychosis and excluded if there was a history of major mental illness or no follow up data were available. RESULTS: Forty-seven patients were included in the quetiapine cohort and 45 in the pimavanserin cohort. Patients in the pimavanserin cohort were more likely to have a diagnosis of DLB (33% vs. 11%, P = 0.01) and to have been prescribed an antipsychotic previously (62% vs. 6%, P < 0.01); otherwise, the groups were similar. Time to discontinuation analysis, which accounts for efficacy, safety and tolerability, revealed a lower early pimavanserin discontinuation rate and a higher late pimavanserin discontinuation rate (HR < 1 before day 43, HR > 1 after day 43; P = 0.04). There was no difference in mortality in the pimavanserin group compared to the quetiapine group (HR 0.37, 95% CI 0.06 to 2.45; P = 0.88). More individuals had a documented secondary indication for taking quetiapine than pimavanserin (38% vs. 4%; P = 0.001). CONCLUSION: Accounting for efficacy, safety and tolerability, pimavanserin may be more clinically useful for promptly managing psychosis, while quetiapine may confer additional secondary benefits long-term.
Authors: Rajesh Pahwa; Kelly E Lyons; Robert A Hauser; Stanley Fahn; Joseph Jankovic; Emmanuelle Pourcher; Ann Hsu; Martin O'Connell; Sherron Kell; Suneel Gupta Journal: Parkinsonism Relat Disord Date: 2013-09-05 Impact factor: 4.891
Authors: Elin B Forsaa; Jan Petter Larsen; Tore Wentzel-Larsen; Christopher G Goetz; Glenn T Stebbins; Dag Aarsland; Guido Alves Journal: Arch Neurol Date: 2010-08
Authors: I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada Journal: Neurology Date: 2005-10-19 Impact factor: 9.910
Authors: Klaus Seppi; K Ray Chaudhuri; Miguel Coelho; Susan H Fox; Regina Katzenschlager; Santiago Perez Lloret; Daniel Weintraub; Cristina Sampaio Journal: Mov Disord Date: 2019-01-17 Impact factor: 10.338
Authors: Chris Stinton; Ian McKeith; John-Paul Taylor; Louise Lafortune; Eneida Mioshi; Elijah Mak; Victoria Cambridge; James Mason; Alan Thomas; John T O'Brien Journal: Am J Psychiatry Date: 2015-06-18 Impact factor: 18.112
Authors: Luis Agüera-Ortiz; Ganesh M Babulal; Marie-Andrée Bruneau; Byron Creese; Fabrizia D'Antonio; Corinne E Fischer; Jennifer R Gatchel; Zahinoor Ismail; Sanjeev Kumar; William J McGeown; Moyra E Mortby; Nicolas A Nuñez; Fabricio F de Oliveira; Arturo X Pereiro; Ramit Ravona-Springer; Hillary J Rouse; Huali Wang; Krista L Lanctôt Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160